Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT03127605
Inotuzumab Ozogamicin - PF-05208773 | NCT03127605 | Trialant
Save
Share
Approved for marketing
Expanded Access
Updated May 18, 2020
Inotuzumab Ozogamicin - PF-05208773
ClinicalTrials.gov ID
NCT03127605
Lead Sponsor
Pfizer
INDUSTRY
Overall Status
Approved for marketing
Study Type
Expanded Access
Last Update Posted
May 18, 2020
Actual
Brief Summary
Inotuzumab Ozogamicin Expanded Access Program
No conditions
There are no conditions for this study.
Inotuzumab Ozogamicin
Ages Eligible for Study
Child (0-17)
Adult (18-64)
Older Adult (65+)
Sexes Eligible for Study
No data available
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
-
Exclusion Criteria:
-
No design
There is no design for this study.
No central contacts
There are no central contacts for this study.
No locations
There are no locations for this study.
Lead Sponsor
Pfizer
INDUSTRY
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
NCT02222922
Completed
Interventional
Phase 1
Updated Dec 17, 2020
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
NCT04171141
Terminated
Interventional
Phase 1
Updated Jan 16, 2025
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
NCT00929903
Completed
Interventional
Phase 1
Updated Sep 30, 2013
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
NCT05233436
Terminated
Interventional
Phase 1
Updated Feb 19, 2026
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
NCT02315066
Completed
Interventional
Phase 1
Updated Apr 21, 2022
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
NCT00788580
Withdrawn
Interventional
Phase 1
Updated Mar 6, 2015